Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-09-28
2009-08-18
Allen, Marianne P (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S007210, C530S387900
Reexamination Certificate
active
07575879
ABSTRACT:
The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4877864 (1989-10-01), Wang et al.
patent: 5013649 (1991-05-01), Wang et al.
patent: 5106748 (1992-04-01), Wozney et al.
patent: 5166058 (1992-11-01), Wang et al.
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 5399677 (1995-03-01), Wolfman et al.
patent: 5453419 (1995-09-01), Murakami et al.
patent: 5543394 (1996-08-01), Wozney et al.
patent: 5620867 (1997-04-01), Kiefer et al.
patent: 5631142 (1997-05-01), Wang et al.
patent: 5637480 (1997-06-01), Celeste et al.
patent: 5641756 (1997-06-01), Robinson
patent: 5661007 (1997-08-01), Wozney et al.
patent: 5670338 (1997-09-01), Murakami et al.
patent: 6235713 (2001-05-01), Achen et al.
patent: 6391311 (2002-05-01), Ferrara et al.
patent: 6455283 (2002-09-01), Ferrara et al.
patent: 6620784 (2003-09-01), Ferrara et al.
patent: 6887982 (2005-05-01), Gao et al.
patent: 2003/0027998 (2003-02-01), Holtzman et al.
patent: 2003/0113870 (2003-06-01), Ferrara et al.
patent: 2004/0138417 (2004-07-01), Fitzpatrick et al.
patent: 2004/0219640 (2004-11-01), Ferrara et al.
patent: 2004/0235740 (2004-11-01), Ferrara et al.
patent: 2005/0282233 (2005-12-01), Eriksson et al.
patent: 471754 (1996-07-01), None
patent: 370989 (1996-09-01), None
patent: WO 88/00205 (1988-01-01), None
patent: WO 94/01548 (1994-01-01), None
patent: WO96/30046 (1996-10-01), None
patent: WO 98/06724 (1998-02-01), None
patent: WO 98/07832 (1998-02-01), None
patent: WO 98/45332 (1998-10-01), None
patent: WO 99/37671 (1999-07-01), None
patent: WO99/46281 (1999-09-01), None
patent: WO 99/46281 (1999-09-01), None
patent: WO 99/47677 (1999-09-01), None
patent: WO 00/04183 (2000-01-01), None
patent: WO 00/18212 (2000-04-01), None
patent: WO 00/24774 (2000-05-01), None
patent: WO 00/32221 (2000-06-01), None
patent: WO 00/34474 (2000-06-01), None
patent: WO 00/37641 (2000-06-01), None
patent: WO 00/39284 (2000-07-01), None
patent: WO 00/53758 (2000-09-01), None
patent: WO 00/59940 (2000-10-01), None
patent: WO 00/66736 (2000-11-01), None
Achen et al., “Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flkl) and VEGF receptor 3 (Flt4)”Proc. Natl. Acad. Sci. USA95(2):548-553 (Jan. 20, 1998).
Adamis et al., “Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate”Arch. Ophthalmology114(1):66-71 (1996).
Aiello et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders”New England J. of Medicine331(22):1480-1487 (1994).
Berkman et al., “Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasm”J. Clin. Invest. 91(1):153-159 (1993).
Borgstrom et al., “Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy”Cancer Research56(17):4032-4039 (Sep. 1, 1996).
Bork, et al., “Go hunting in sequence databases but watch out for the traps”Trends in Genetics12(10):425-427 (Oct. 1996).
Bork, P., “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle”Genome Research10(4):398-400 (Apr. 2000).
Brenner, S.E., “Errors in genome annotation”Trends in Genetics15(4):132-133 (Apr. 1999).
Brown et al., “Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract”Cancer Research53(19):4727-4735 (1993).
Brown et al., “Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer”Human Pathology26(1):86-91 (1995).
Burgess and Maciag, “The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins”Annu. Rev. Biochem. 58:575-606 (1989).
Clapp et al., “The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis”Endocrinology133(3):1292-1299 (1993).
Connolly et al., “Human Vascular Permeability Factor”Journal of Biological Chemistry264(33):20017-20024 (1989).
Doerks, et al., “Protein annotation: detective work for function prediction”Trends in Genetics14(6):248-250 (Jun. 1998).
Duesterhoeft et al., “Locue AI040028, Mar. 10, 1998, Accessed Feb. 26, 2000”German Genome Project.
Dvorak et al., “Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis”American Journal of Pathology146(5):1029-1039 (1995).
Einhorn, M.D. Lawrence H., “Charles F. Kettering Prize. Clinical trials in testicular cancer”Cancer71(10):3182-3184 (May 15, 1993).
““EMBL Database Accesion No. AA631149””.
Ferrara and Davis-Smyth, “The Biology of Vascular Endothelial Growth Factor”Endocrine Reviews18(1):4-25 (1997).
Ferrara and Henzel, “Pituitary Follicular Cells Secrete a Novel Heparin-binding Growth Factor Specific for Vascular Endothelial Cells”Biochem. &Biophys. Res. Comm. 161(2):851-858 (Jun. 15, 1989).
Ferrara et al., “Molecular and biological properties of the vascular endothelial growth factor family of proteins”Endo. Rev. 13(1):18-32 (Feb. 1992).
Ferrara et al., “The vascular endothelial growth factor family of polypeptides”J. Cell. Biochem. 47:211-218 (1991).
Folkman and Shing, “Angiogenesis”Biol Chem. 267(16):10931-10934 (Jun. 5, 1992).
Folkman et al., “Induction of angiogenesis during the transition from hyperplasia to neoplasia”Nature339(6219):58-61 (1989).
Gayle et al., “Identification of regions in interleukin-1 alpha important for activity”Journal of Biological Chemistry268(29):22105-22111 (Oct. 1993).
Good et al., “A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin”Proc. Natl. Acad. Sci. USA87(17):6624-6628 (1990).
Hillier et al., “Generation and Analysis of 280,000 Human Expressed Sequence Tags”Genome Research6 (9):807-828 (1996).
Hollenbaugh, et al., “Recombinant globulins: novel research tools and possible pharmaceuticals”Current Protocols in Immunology2:10.19.1-10.19-.11 (Apr. 1992).
Horak et al., “Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer”Lancet340 (8828):1120-1124 (1992).
Houck et al., “The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA”Mol. Endocrinol. 5(12):1806-1814 (Dec. 1991).
Ishikaw et al., “Identification of Angiogenic Activity and the Cloning and Expression of Platelet-Derived Endothelial Cell Growth Factor.”Nature. 338:557-562 (1989).
Keck et al., “Vascular Permeability Factor, An Endothelial Cell Mitogen Related to PDGF”Science246:1309-1312 (1989).
Kim et al., “Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in vivo”Nature362:841-844 (Apr. 29, 1993).
Klagsbrun and D'Amore, “Regulators of angiogenesis”Ann. Rev. Physiol. 53:217-239 (1991).
Leung et al., “Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen”Science246 (4935):1306-1309 (Dec. 8, 1989).
Levine et al., &
Ferrara Napoleone
Kuo Sophia S.
Allen Marianne P
Fang Carol A.
Genentech Inc.
Genentech, Inc
LandOfFree
Polypeptides homologous to VEGF and BMP1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptides homologous to VEGF and BMP1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides homologous to VEGF and BMP1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4061808